中华老年多器官疾病杂志
中華老年多器官疾病雜誌
중화노년다기관질병잡지
CHINESE JOURNAL OF MULTIPLE ORGAN DISEASES IN THE ELDERLY
2015年
8期
612-615
,共4页
老年人%晚期%结直肠肿瘤%治疗结果%药物和物质代谢副作用%生存质量%抗肿瘤药
老年人%晚期%結直腸腫瘤%治療結果%藥物和物質代謝副作用%生存質量%抗腫瘤藥
노년인%만기%결직장종류%치료결과%약물화물질대사부작용%생존질량%항종류약
aged%advanced%colorectal neoplasms%treatment outcome%metabolic side effects of drugs and substances%quality of life%antineoplastic agents
目的：观察卡培他滨单药治疗老年晚期结直肠癌的近期疗效、毒副反应及对生存质量的影响。方法入选2009年10月至2014年2月在北京老年医院肿瘤科治疗的39例具有可测量指标的老年晚期结直肠癌患者，其中男26例，女13例，年龄69～82（73.2±2.5）岁，采用单药卡培他滨化疗，所有患者均给予卡培他滨，连服14d，休息7d（1个周期）每2个周期判定疗效及毒副反应；化疗前及化疗结束后6周采用欧洲癌症研究组织（EORTC）开发的生存质量测定量表（QLQ-C30）测评生存质量。结果39例患者中完全缓解1例、部分缓解11例、稳定18例、进展9例，有效率30.76%，疾病控制率为76.92%；毒副反应为手足综合征（61.54%）、骨髓抑制（66.67%）、皮肤色素沉着（64.10%）等，程度轻；患者的躯体功能、角色功能、社会功能及总体健康得分较化疗前提高（P＜0.05）。结论卡培他滨单药治疗老年晚期结直肠癌近期疗效较好，毒副反应轻，可改善患者生存质量。
目的：觀察卡培他濱單藥治療老年晚期結直腸癌的近期療效、毒副反應及對生存質量的影響。方法入選2009年10月至2014年2月在北京老年醫院腫瘤科治療的39例具有可測量指標的老年晚期結直腸癌患者，其中男26例，女13例，年齡69～82（73.2±2.5）歲，採用單藥卡培他濱化療，所有患者均給予卡培他濱，連服14d，休息7d（1箇週期）每2箇週期判定療效及毒副反應；化療前及化療結束後6週採用歐洲癌癥研究組織（EORTC）開髮的生存質量測定量錶（QLQ-C30）測評生存質量。結果39例患者中完全緩解1例、部分緩解11例、穩定18例、進展9例，有效率30.76%，疾病控製率為76.92%；毒副反應為手足綜閤徵（61.54%）、骨髓抑製（66.67%）、皮膚色素沉著（64.10%）等，程度輕；患者的軀體功能、角色功能、社會功能及總體健康得分較化療前提高（P＜0.05）。結論卡培他濱單藥治療老年晚期結直腸癌近期療效較好，毒副反應輕，可改善患者生存質量。
목적：관찰잡배타빈단약치료노년만기결직장암적근기료효、독부반응급대생존질량적영향。방법입선2009년10월지2014년2월재북경노년의원종류과치료적39례구유가측량지표적노년만기결직장암환자，기중남26례，녀13례，년령69～82（73.2±2.5）세，채용단약잡배타빈화료，소유환자균급여잡배타빈，련복14d，휴식7d（1개주기）매2개주기판정료효급독부반응；화료전급화료결속후6주채용구주암증연구조직（EORTC）개발적생존질량측정량표（QLQ-C30）측평생존질량。결과39례환자중완전완해1례、부분완해11례、은정18례、진전9례，유효솔30.76%，질병공제솔위76.92%；독부반응위수족종합정（61.54%）、골수억제（66.67%）、피부색소침착（64.10%）등，정도경；환자적구체공능、각색공능、사회공능급총체건강득분교화료전제고（P＜0.05）。결론잡배타빈단약치료노년만기결직장암근기료효교호，독부반응경，가개선환자생존질량。
ObjectiveTo observe the short-term efficacy, side effects, impact on quality of life (QOL) of capecitabine alone in treating elderly patients with advanced colorectal cancer.Methods Thirty-nine elderly patients [aged (73.2±2.5) years, ranging from 69 to 82 years] with pathological identified advanced colorectal cancer admitted in our hospital from October 2009 to February 2014 were enrolled in this study, and they all were treated with 2500mg/(m2·d) capecitabine for 14 consecutive days and an interval of 7d (a cycle). The effectiveness and side effects were evaluated for every 2 cycles. Quality of Life Questionnaire (QLQ-C30), designed by European Organization for Research on Treatment of Cancer (EORTC), was conducted on the patients before and in 6 weeks after the therapy.Results Among the 39 patients, there were 1 case of complete remission, 11 cases of partial remission, 18 cases of stable disease, and 9 cases of progressive disease. The efficient rate was 30.76%, and tumor control rate was as high as 76.92%. The main side effects were hand-foot syndrome (61.54%), bone marrow depression (66.67%), and skin pigmentation (64.10%), and all these symptoms were mild. Their physical function, role function, social function and overall health score were increased significantly when compared with the conditions before treatment (P<0.05).Conclusion Capecitabine therapy alone is effective and only causes mild side effects for the elderly patients with advanced colorectal cancer, and it also improves their QOL.
